 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > The Liposome Company, Inc.
 |
The Liposome Company, Inc. |
 |
 |
 |
PROFILE |
 |
The Liposome Company, bought in 2000 by Irish pharmaceutical firm Elan, develops and markets lipid- and liposome-based drugs for treating cancer and other illnesses. The company's first product, ABELCET, combats severe fungal infections in patients with weakened immune systems. The drug is sold in the US (about 80% of sales) and some two dozen other countries. Myocet, a treatment for metastatic breast cancer, is approved in Europe. Utilizing its liposomal technology, the company is also developing treatments for breast, prostate, lung, and other cancers; bromotaxane, a drug in development, may fight ovarian cancer. The Liposome Company is also working on a gene-based drug-delivery system.
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 86.20
1-Yr. Sales Growth: 17.3%
Employees: 306
Revenue per employee: $281,699.35
KEY PEOPLE |
 |
Charles A. Baker
CEO
Lawrence R. Hoffman
CFO
CONTACT INFO |
 |
1 Research Way
Princeton, NJ 08540
US
Phone: 609-452-7060
Fax: 609-452-1890
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |